07:00 , Mar 15, 2010 |  BC Week In Review  |  Clinical News

NMP22 BladderChek Test: Post-marketing study data

Researchers at the M.D. Anderson Cancer Center reported data from a prospective analysis of 2009 Medicare reimbursement data from 200 patients with non-muscle invasive bladder cancer showing that cystoscopy alone, the standard of care, was...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Company News

Inverness, Matritech deal

IMA will acquire substantially all of MZT's assets for $36 million in stock, which is the equivalent of $0.58 for each of MZT's 62 million outstanding shares. The price is a 190% premium to MZT's...
08:00 , Jan 23, 2006 |  BC Week In Review  |  Clinical News

NMP22 BladderChek Test diagnostic data

In a U.S. trial in 668 patients with a history of bladder cancer, NMP22 assay in combination with cytoscopy detected recurrence of bladder cancer in 102 of 103 (99%) patients, who were positive for bladder...
07:00 , Jul 18, 2005 |  BC Week In Review  |  Clinical News

NMP22 BladderChek Test regulatory update

MZT received Japanese marketing approval for NMP22 BladderCheck test, an assay to detect nuclear matrix protein NMP22 in urine, to diagnose bladder cancer. BladderChek is approved in the U.S., Europe and Canada. Matritech Inc. (MZT),...
08:00 , Feb 21, 2005 |  BC Week In Review  |  Clinical News

NMP22 BladderChek Test diagnostic data

In a U.S. study in 1,331 patients at risk for bladder cancer, the NMP22 BladderChek test with cytoscopy detected 94% of the bladder cancers compared to 89% seen by cytoscopy alone (p=0.26). Of the 79...
07:00 , Sep 27, 2004 |  BC Week In Review  |  Clinical News

NMP22 BladderChek regulatory update

Matritech Inc. (MZT), Newton, Mass.   Product: NMP22 BladderChek   Business: Diagnostic   Health Canada approved NMP22 BladderChek, an assay to detect nuclear matrix protein NMP22 in urine, to diagnose and monitor bladder cancer. Stellar...
07:00 , Jun 14, 2004 |  BC Week In Review  |  Company News

Matritech, Inverness sales and marketing update

MZT granted Wampole Laboratories LLC (Princeton, N.J.), a subsidiary of IMA, exclusive rights to distribute the NMP 22 ELISA test kit to hospitals and clinical reference laboratories in the U.S. MZT will continue to sell...
08:00 , Feb 23, 2004 |  BC Week In Review  |  Clinical News

NMP22 BladderCheck test regulatory update

MZT received CE Mark approval in the EU for its NMP22 products, including NMP22 BladderChek to detect the bladder cancer matrix protein NMP22 in urine. Matritech Inc. (MZT), Newton, Mass.   Product: NMP22 BladderCheck test...
08:00 , Oct 27, 2003 |  BC Week In Review  |  Company News

Matritech, Stellar International Inc. deal

Canadian specialty pharma company SSY received exclusive rights to market NMPS's NMP22 BladderChek test to diagnose and monitor bladder cancer. BladderChek is approved by the FDA for use in physicians offices to diagnose and monitor...
07:00 , Oct 24, 2003 |  BC Extra  |  Company News

Stellar, Matritech bladder diagnostic deal

Canadian specialty pharma company Stellar (TSE:YYS; SLRXF) received exclusive rights to market NMPS's NMP22 BladderChek test to diagnose and monitor bladder cancer. BladderChek is approved by FDA for use in physicians offices to diagnose and...